Answers are grounded in this paper and cite their sources.
Background Colonoscopy surveillance for colorectal cancer (CRC) is invasive, burdensome and costly for patients with inflammatory bowel disease (IBD). Aim To reduce colonoscopy frequency, we assessed the potential of faecal volatile organic compounds (VOCs) as non-invasive biomarkers to detect colorectal dysplasia in IBD. Methods Exploratory study in which patients with IBD collected faeces in the three months before surveillance colonoscopy. Faecal VOCs were analysed using field asymmetric ion mobility spectrometry followed by machine learning pipelines. Mucosal remission was defined as Mayo 0–1 (ulcerative colitis), SES-CD 0–2 (Crohn’s Disease) or Rutgeerts i0–i1 (postoperative Crohn’s disease). Results Among 46 included patients (median 57 years, 54% male, 63% ulcerative colitis), 14 patients had dysplasia at colonoscopy, which was mostly low-grade and did not involve CRC. During mucosal remission (the ideal setting for surveillance), faecal VOCs detected colorectal dysplasia with 100% sensitivity at 50% specificity. Irrespective of mucosal activity – which would be unknown at the time of future faeces sampling – colorectal dysplasia was detected with 93% sensitivity at 38% specificity. Conclusions Faecal VOCs may have potential to detect (early stage) colorectal dysplasia in IBD. Our results serve as a stepping stone for large validation studies that also consider accuracy for advanced dysplasia, patient acceptability, and confounders – in an effort to reduce colonoscopy burden in IBD.
No takes yet. Share an insight, caveat, or question.
Liere et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: